Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [4] Group 1: Event Participation - The CEO, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27 Annual Global Investment Conference from September 8-10, 2025 [1] - The fireside chat is scheduled for September 10, 2025, from 12:30 to 1:00 p.m. EDT at the Lotte New York Palace Hotel [2] - During the conference, Dr. Vera and the management team will hold one-on-one meetings with registered investors to discuss the Multi-Antigen Recognizing (MAR) T cell platform and clinical developments, including updates on the Phase 1 APOLLO study [2] Group 2: Company Overview - Marker Therapeutics was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated with durable clinical responses [4] - The company aims to introduce novel T cell therapies to the market to improve patient outcomes while prioritizing financial resource preservation and operational excellence [4] - Marker’s T cell platform benefits from non-dilutive funding from U.S. state and federal agencies supporting cancer research [4]